Malvern, PA
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
xylocor.comThese are collections XyloCor Therapeutics is a part of. Click on the collection name to view similar companies.
Series B
$67,500,000
Series A
$22,600,000
Series A
$17,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on XyloCor Therapeutics.